These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 21150787)

  • 21. Influence of proband's characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G20210A polymorphisms.
    Bucciarelli P; De Stefano V; Passamonti SM; Tormene D; Legnani C; Rossi E; Castaman G; Simioni P; Cini M; Martinelli I
    Blood; 2013 Oct; 122(15):2555-61. PubMed ID: 23913469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The risk of major bleeding in patients with factor V Leiden or prothrombin G20210A gene mutation while on extended anticoagulant treatment for venous thromboembolism.
    Caiano L; Kovacs MJ; Lazo-Langner A; Anderson DR; Kahn SR; Shah V; Kaatz S; Zide RS; Schulman S; Chagnon I; Mallick R; Rodger MA; Wells PS
    J Thromb Haemost; 2023 Mar; 21(3):553-558. PubMed ID: 36710196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of inherited thrombophilia on the risk of recurrent venous thromboembolism onset in Georgian population.
    Pirtskhelani N; Kochiashvili N; Makhaldiani L; Pargalava N; Gaprindashvili E; Kartvelishvili K
    Georgian Med News; 2014 Feb; (227):93-7. PubMed ID: 24632656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of placenta-mediated pregnancy complications or pregnancy-related VTE in VTE-asymptomatic families of probands with VTE and heterozygosity for factor V Leiden or G20210 prothrombin mutation.
    Cordoba I; Pegenaute C; González-López TJ; Chillon C; Sarasquete ME; Martin-Herrero F; Guerrero C; Cabrero M; Garcia Sanchez MH; Pabon P; Lozano FS; Gonzalez M; Alberca I; González-Porras JR
    Eur J Haematol; 2012 Sep; 89(3):250-5. PubMed ID: 22642978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of factor V G1691A (Leiden) and prothrombin G20210A polymorphisms among apparently healthy Jordanians.
    Nusier MK; Radaideh AM; Ababneh NA; Qaqish BM; Alzoubi R; Khader Y; Mersa JY; Irshaid NM; El-Khateeb M
    Neuro Endocrinol Lett; 2007 Oct; 28(5):699-703. PubMed ID: 17984931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multilocus genetic risk scores for venous thromboembolism risk assessment.
    Soria JM; Morange PE; Vila J; Souto JC; Moyano M; Trégouët DA; Mateo J; Saut N; Salas E; Elosua R
    J Am Heart Assoc; 2014 Oct; 3(5):e001060. PubMed ID: 25341889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pregnancy-associated venous thromboembolism (VTE) in combined heterozygous factor V Leiden (FVL) and prothrombin (FII) 20210 A mutation and in heterozygous FII single gene mutation alone.
    Samama MM; Rached RA; Horellou MH; Aquilanti S; Mathieux VG; Plu-Bureau G; Elalamy I; Conard J
    Br J Haematol; 2003 Oct; 123(2):327-34. PubMed ID: 14531916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review.
    Ho WK; Hankey GJ; Quinlan DJ; Eikelboom JW
    Arch Intern Med; 2006 Apr; 166(7):729-36. PubMed ID: 16606808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombosis risk in single- and double-heterozygous carriers of factor V Leiden and prothrombin G20210A in FinnGen and the UK Biobank.
    Ryu J; Rämö JT; Jurgens SJ; Niiranen T; Sanna-Cherchi S; Bauer KA; Haj A; Choi SH; Palotie A; Daly M; Ellinor PT; Bendapudi PK
    Blood; 2024 Jun; 143(23):2425-2432. PubMed ID: 38498041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High prevalence of factor V Leiden and prothrombin G20101A mutations in Kashmiri patients with venous thromboembolism.
    Shafia S; Zargar MH; Khan N; Ahmad R; Shah ZA; Asimi R
    Gene; 2018 May; 654():1-9. PubMed ID: 29454086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct blood PCR: TaqMan-probe based detection of the venous thromboembolism associated mutations factor V Leiden and prothrombin c.20210G>A without DNA extraction.
    Geiger K; Leiherer A; Brandtner EM; Fraunberger P; Drexel H; Muendlein A
    Clin Chim Acta; 2019 Jan; 488():221-225. PubMed ID: 30439355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic Risk Factors of Venous Thromboembolism in the East Algerian Population.
    Moussaoui S; Saussoy P; Ambroise J; Defour JP; Zouitene R; Sifi K; Abadi N
    Clin Appl Thromb Hemost; 2017 Mar; 23(2):105-115. PubMed ID: 26304686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of the factor II: G20210A variant on the risk of venous thromboembolism in relatives from families with the factor V: R506Q mutation.
    Rintelen C; Pabinger I; Bettelheim P; Lechner K; Kyrle PA; Knöbl P; Schneider B; Mannhalter C
    Eur J Haematol; 2001 Sep; 67(3):165-9. PubMed ID: 11737249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obstetric complications and pregnancy-related venous thromboembolism: the effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation.
    Tormene D; Grandone E; De Stefano V; Tosetto A; Palareti G; Margaglione M; Castaman G; Rossi E; Ciminello A; Valdrè L; Legnani C; Tiscia GL; Bafunno V; Carraro S; Rodeghiero F; Simioni P
    Thromb Haemost; 2012 Mar; 107(3):477-84. PubMed ID: 22273731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
    Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
    Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of point mutations in the genes, predisposing inherited thrombophilia in the pathogeneses of proximal and distal deep vein thrombosis in Georgian population.
    Pirtskhelani N; Kochiashvili N; Makhaldiani L; Pargalava N; Gaprindashvili E; Kartvelishvili K
    Georgian Med News; 2014 Feb; (227):98-102. PubMed ID: 24632657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factor V Leiden and prothrombin 20210G>A [corrected] mutation and paediatric ischaemic stroke: a case-control study and two meta-analyses.
    Laugesaar R; Kahre T; Kolk A; Uustalu U; Kool P; Talvik T
    Acta Paediatr; 2010 Aug; 99(8):1168-74. PubMed ID: 20337781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thrombophilic risk of individuals with rare compound factor V Leiden and prothrombin G20210A polymorphisms: an international case series of 100 individuals.
    Lim MY; Deal AM; Kim S; Musty MD; Conard J; Simioni P; Dutrillaux F; Eid SS; Middeldorp S; Halbmayer WM; Boneu B; Moia M; Moll S
    Eur J Haematol; 2016 Oct; 97(4):353-60. PubMed ID: 26773706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation.
    Tzoran I; Papadakis M; Brenner B; Fidalgo Á; Rivas A; Wells PS; Gavín O; Adarraga MD; Moustafa F; Monreal M;
    Am J Med; 2017 Apr; 130(4):482.e1-482.e9. PubMed ID: 27986523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.